^
Association details:
| Biomarker: | TMB-H + PD-L1 expression |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
296P - Tumour mutational burden and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: Exploratory analysis of the phase III IMpassion130 trial
Published date:
09/14/2020
Excerpt:
...higher TMB was associated with OS benefit in PD-L1+ TNBC treated with Az + nP…
Secondary therapy:
albumin-bound paclitaxel
Trial ID:
